trending Market Intelligence /marketintelligence/en/news-insights/trending/rIePglceRI_ArJ7pXHwHeg2 content esgSubNav
In This List

ANI Pharmaceuticals buys US rights to 4 AstraZeneca drugs for $46.5M

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


ANI Pharmaceuticals buys US rights to 4 AstraZeneca drugs for $46.5M

ANI Pharmaceuticals, Inc. said it purchased U.S. rights to four of AstraZeneca PLC's drugs for $46.5 million.

The drugs include hypertension treatments Atacand and Atacand HCT, breast cancer medicine Arimidex, and Casodex for prostate cancer.

AstraZeneca, the U.K.'s second-biggest drugmaker, will continue to market and supply these four drugs outside the U.S. The British drugmaker has been selling off older assets as it focuses on developing new products.

The payment of $46.5 million would be in cash, royalties and sales-based milestones. ANI funded the acquisitions through a combination of cash and debt.

According to market intelligence firm IMS Health, these products generated about $19 million in U.S. sales during the trailing 12 months through October 2017.

ANI, based in Baudette, Minn., sells both branded and generic prescription drugs.